0000939767-26-000059
SEC filingQ1 delivered strong revenue growth and exceptional profitability expansion driven by CABOMETYX sales volume increases from longer therapy durations and operational efficiencies, enabling robust cash generation despite liquidity reduction from capital returns.
Exelixis reported robust Q1 FY2026 financial results, with revenue of $610.8 million, up 10.0% from $555.4 million in the prior year period. This growth stemmed from increased sales volume, largely driven by refills that reflect the longer duration of therapy for CABOMETYX in combination with nivolumab, alongside market share gains in the evolving metastatic renal cell carcinoma (RCC) and neuroendocrine tumor (NET) landscapes. Gross profit expanded 10.2% to $590.9 million, achieving a 96.7% gross margin. The modest increase in cost of goods sold was primarily due to higher royalties linked to elevated U.S. sales, but this was more than offset by the strong top-line performance, demonstrating sustained pricing power and cost control in product delivery.
Operating income surged 34.5% to $251.3 million, representing a 41.1% operating margin—well above the prior year's levels. This exceptional operating leverage highlights the company's ability to scale profitability as revenues grow, with expense discipline amplifying the benefits of higher-margin product sales. Net income followed suit, rising 31.9% to $210.5 million, translating to diluted EPS of $0.79, a 43.6% improvement from $0.55. These gains underscore how revenue momentum and efficiency directly enhance shareholder value through bottom-line expansion.